profile icon
Prof

Phillip Darcy

Honorary
The Sir Peter MacCallum Department of Oncology
science & technology
life sciences & biomedicine
humans
animals
immunology
oncology
mice
immunotherapy
neoplasms
Phillip Darcy's Profile Picture
Prof

Phillip Darcy

 
Division
Medicine, Dentistry and Health Sciences
 
Primary Interest
Microbiology and Biochemistry
Phillip Darcy's Profile Picture
Prof

Phillip Darcy

 
Print
Phillip's  Short Profile
 

Projects

Displaying the 10 most recent projects by Phillip Darcy.

Project icon

A NOVEL APPROACH TO ENABLE CAR T CELLS TO ENGAGE THE HOST IMMUNE SYSTEM AND OVERCOME THE HETEROGENEITY OF SOLID TUMOURS

2020 - 2023
Active
Project icon

CHARACTERISING THE MOLECULAR AND IMMUNE LANDSCAPES OF METASTATIC BREAST CANCER USING A RAPID AUTOPSY PROGRAM

2019 - 2022
Active
Project icon

ENHANCING IMMUNE CELL TRAFFICKING TO TUMOURS TO IMPROVE THE THERAPY OF BREAST CANCER

2019 - 2023
Active
Project icon

USING LESSONS FROM TOXIC SHOCK SYNDROME TO ENHANCE BREAST CANCER IMMUNOTHERAPY

2018 - 2020
Completed
Project icon

INVESTIGATING THE POTENTIAL OF MUCOSAL ASSOCIATED INVARIANT T (MAIT) CELLS IN CANCER

This award will support several workshops to catalyze the ecosystem science community to address research frontiers, opportunities and chall..

2018 - 2020
Completed
Project icon

NEW STRATEGIES FOR ENHANCING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR CANCER

The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet ..

2018 - 2022
Active
Project icon

IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

2018 - 2022
Active
Project icon

EXPLOITING AND DEFINING THE IMMUNE REGULATORY ACTIVITIES OF BET BROMODOMAIN INHIBITORS

Immune-based agents such as “checkpoint inhibitors” have the ability to re-awaken our own immune systems and activate previously dormant ant..

2017 - 2018
Completed
Project icon

COMBINING PI3K, CDK4/6 PATHWAY INHIBITORS AND CHECKPOINT BLOCKADE IN TRIPLE-NEGATIVE BREAST CANCER

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characteri..

2017 - 2019
Completed
Project icon

TYPE 1 INTERFERON REGULATORS AS PROGNOSTIC MARKERS AND PREDICTORS OF THERAPEUTIC RESPONSE IN TRIPLE NEGATIVE BREAST CANCER

2017 - 2020
Completed

28

Projects

Project Types

28

Research Grant

Scholarly Works

Displaying the 10 most recent scholarly works by Phillip Darcy.

Scholarly works icon

Cellular networks controlling T cell persistence in adoptive cell therapy.

Jack D Chan, Junyun Lai, Clare Y Slaney, Axel Kallies, Paul A Beavis, Phillip K Darcy

Journal article  |  2021  |  Nature Reviews Immunology

The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is highly dependent on their differentiati..

Scholarly works icon

Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2 murine model

Ran Li, Sneha Sant, Emmaline Brown, Franco Caramia, Ann Byrne, Kylie Clarke, Michael Neeson, Paul J Neeson, Phillip K Darcy, Scott Peterson, Sherene Loi

Conference Proceedings  |  2021  |  Poster Session Abstracts

Scholarly works icon

Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment

Samuel S Widodo, Ryan A Hutchinson, Yitong Fang, Stefano Mangiola, Paul J Neeson, Phillip K Darcy, Alexander D Barrow, Christopher M Hovens, Marija Dinevska, Stanley S Stylli, Theo Mantamadiotis

Journal article  |  2021  |  Cancer Immunology, Immunotherapy

Recent developments in cancer immunotherapy promise better outcomes for cancer patients, although clinical trials for difficult to..

Scholarly works icon

IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Imran G House, Junyun Lai, Amanda XY Chen, Kirsten L Todd, Emma Petley, Sherly Mardiana, Izabela Todorovski, Emily Gruber, Madison J Kelly, Benjamin J Solomon, Stephin J Vervoort, Ricky W Johnstone, Ian A Parish, Paul J Neeson, Lev M Kats, Phillip K Darcy, Paul A Beavis

Journal article  |  2020  |  Molecular Therapy

Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological malignancies leading to their US Food a..

Scholarly works icon

NOVEL COMBINATION IMMUNOTHERAPY FOR BOOSTING AND PRIMING IMMUNE RESPONSES IN PANCREATIC CANCER: STRONG ANTI-TUMOUR EFFECTS WITH INTERLEUKIN-15 AND CD40 AGONIST TREATMENT

Jonas Van Audenaerde, Elly Marcq, Bianca von Scheidt, Ashleigh Davey, Amanda Oliver, Jorrit De Waele, Delphine Quatannens, Jinthe Van Loenhout, Patrick Pauwels, Geert Roeyen, Filip Lardon, Clare Slaney, Marc Peeters, Michael Kershaw, Phillip Darcy, Evelien Smits

Conference Proceedings  |  2020  |  Journal for ImmunoTherapy of Cancer

Scholarly works icon

EARLY-PHENOTYPE LEWIS Y CAR-T CELLS PERSIST BETTER IN VIVO AND INDUCE SOLID TUMOR REGRESSION IN COMBINATION WITH ANTI-PD1

Deborah Meyran, Joe Zhu, Jeanne Butler, Sean Macdonald, Daniela Tantalo, Niko Thio, Kevin Sek, Paul Ekert, Michael Kershaw, Joe Trapani, Phillip Darcy, Paul Neeson

Conference Proceedings  |  2020  |  Journal for ImmunoTherapy of Cancer

Scholarly works icon

580 High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot

Simon Keam, Heloise Halse, ThuNgoc Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David Byrne, Sue Haupt, Georgina Ryland, Phillip Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott Williams, Paul Neeson

Conference Proceedings  |  2020  |  Journal for ImmunoTherapy of Cancer

BackgroundProstate cancer is frequently cured with high dose-rate brachytherapy (HDRBT) radiation as a front-line treatment. Altho..

Scholarly works icon

Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer

Kevin Sek, Lev M Kats, Phillip K Darcy, Paul A Beavis

Journal article  |  2020  |  Current Opinion in Pharmacology

Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the pa..

Scholarly works icon

Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses

Amanda J Oliver, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney

Journal article  |  2020  |  Journal of Thoracic Disease

Scholarly works icon

Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities

Jack D Chan, Aaron J Harrison, Phillip K Darcy, Michael H Kershaw, Clare Y Slaney

Journal article  |  2020  |  Journal of Thoracic Disease

181

Scholarly Works

Keyword Analysis

Oncology and Carcinogenesis
Clinical Health (organs, Diseases and Abnormal Conditions)
Immunology
Expanding Knowledge
Clinical (organs, Diseases and Abnormal Conditions)
Clinical Sciences
Biochemistry and Cell Biology
Medical Microbiology
Non-Oriented Research
Other Medical and Health Sciences

Honours, Awards and Fellowships

1992

Commonwealth Post-graduate Scholarship
1991

Travel grant from Australian Society for Microbiology to attned the 1991 meeting, Brisbane
1990

Poster award, Australia and New Zealand Society for Cell Biology, 8th Annual Meeting, Melbourne

3

Awards

Credentials

Positions

Honorary

The Sir Peter MacCallum Department of Oncology

Honorary

Clinical Pathology

Member

Australian Society for Biochemistry and Molecular Biology

Member

Australian Society for Microbiology

Education

Doctor of Philosophy

University of Melbourne

Bachelor of Science

La Trobe University

Links